Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $16.1 million.

  • Arrowhead Pharmaceuticals' Net Income towards Common Stockholders rose 109.30% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 104.93%. This contributed to the annual value of $30.1 million for FY2025, which is 104.94% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Net Income towards Common Stockholders of $16.1 million as of Q3 2025, which was up 109.02% from -$178.7 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders registered a high of $367.8 million during Q1 2025, and its lowest value of -$178.7 million during Q2 2025.
  • In the last 3 years, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$127.0 million in 2024 and averaged -$67.9 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Net Income towards Common Stockholders crashed by 366.37% in 2024 and then surged by 389.63% in 2025.
  • Arrowhead Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$62.9 million in 2021, then skyrocketed by 33.50% to -$41.8 million in 2022, then slumped by 223.78% to -$135.4 million in 2023, then declined by 29.43% to -$175.2 million in 2024, then spiked by 109.30% to $16.1 million in 2025.
  • Its Net Income towards Common Stockholders was $16.1 million in Q3 2025, compared to -$178.7 million in Q2 2025 and $367.8 million in Q1 2025.